Physician profile
Anthony Ricketti
NPI 1285680850
$225,184.42
in general payments reported to CMS, 2019-2025
56 companies · $13K in 2025
The $13K reported for 2025 was more than what 94% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $11K · 2021: $23K · 2022: $34K · 2023: $86K · 2024: $49K · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $130K · Food and Beverage: $13K · Travel and Lodging: $3,721 · Education: $295 · Consulting Fee: $17.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $130,325.00 |
| Food and Beverage | $13,343.57 |
| Travel and Lodging | $3,721.22 |
| Education | $295.34 |
| Consulting Fee | $17.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $208,115.19 | 2019-2025 | Arexvy, Trelegy Ellipta, Nucala |
| Astrazeneca Pharmaceuticals Lp | $6,518.13 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Genentech USA, INC. | $2,059.90 | 2019-2025 | Xolair |
| Csl Behring | $833.71 | 2019-2025 | Hizentra, Andembry, Haegarda |
| Genzyme Corporation | $716.08 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $664.52 | 2019-2025 | Dupixent |
| Jazz Pharmaceuticals INC. | $558.03 | 2019-2025 | |
| Amgen INC. | $527.89 | 2022-2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $497.52 | 2020-2025 | Hyqvia, Cuvitru, Takhzyro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $439.37 | 2019-2025 | Spiriva Respimat, Ofev, Spiriva |
| Optinose US, INC. | $395.97 | 2019-2025 | |
| Pfizer INC. | $392.45 | 2019-2025 | |
| Grifols USA, LLC | $345.52 | 2019-2025 | Prolastin-C Liquid, Xembify |
| Insmed, INC. | $340.75 | 2019-2025 | Brinsupri, Arikayce |
| Sunovion Pharmaceuticals INC. | $281.81 | 2019-2021 |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $225.05 | 2025 | Ohtuvayre |
| Leo Pharma INC. | $192.95 | 2023-2025 | Adbry |
| Ars Pharmaceuticals Operations, INC. | $187.79 | 2025 | Neffy |
| Novartis Pharmaceuticals Corporation | $156.81 | 2024-2025 | |
| Covis Pharma Gmbh | $151.81 | 2021-2022 | |
| Axsome Therapeutics, INC. | $130.87 | 2024-2025 | Sunosi |
| Bio Products Laboratory USA, INC. | $118.35 | 2019-2023 | Gammaplex, Coagadex |
| Harmony Biosciences LLC | $100.08 | 2021-2025 | Wakix |
| United Therapeutics Corporation | $95.84 | 2022-2025 | Tyvaso, Tyvaso |
| Pharming Healthcare, INC. | $88.54 | 2019-2024 | Ruconest |
| Biocryst US Sales Co., LLC | $79.00 | 2022-2025 | Orladeyo |
| Blueprint Medicines Corporation | $77.97 | 2022-2024 | Ayvakit |
| Teva Pharmaceuticals USA, INC. | $74.11 | 2019-2022 | |
| Mylan Specialty L.P. | $70.71 | 2019-2024 | Yupelri |
| Electromed, INC. | $59.91 | 2022-2024 | Smartvest |
| Lilly USA, LLC | $57.02 | 2025 | Ebglyss, Zepbound |
| Philips North America LLC | $55.98 | 2019-2020 | |
| Gc Biopharma USA, INC. | $43.38 | 2025 | Alyglo |
| Kaleo, INC. | $42.63 | 2019-2024 | Auvi-Q |
| Aimmune Therapeutics, INC. | $38.64 | 2020-2021 | |
| Uswm, LLC | $33.00 | 2021 | |
| Galderma Laboratories, L.P. | $32.70 | 2025 | Nemluvio |
| Abbvie INC. | $31.31 | 2023-2024 | |
| Mallinckrodt Enterprises LLC | $29.32 | 2019 | |
| Greer Laboratories, INC. | $27.54 | 2024-2025 | Oralair |
| Shire North American Group INC | $27.54 | 2019 | |
| Circassia INC. | $26.84 | 2019 | |
| Ani Pharmaceuticals, INC. | $22.64 | 2025 | Purified Cortrophin Gel |
| Merck Sharp & Dohme LLC | $22.27 | 2023 | |
| Pulmonx Corporation | $19.34 | 2022 | |
| Ionis Pharmaceuticals, INC. | $18.00 | 2025 | Dawnzera |
| Baxter Healthcare | $17.99 | 2023 | Hillrom - Vest System Model 105 Home Care |
| Adma Biomanufacturing LLC | $17.54 | 2025 | |
| Phadia US INC. | $17.38 | 2023 | Immunocap |
| Paratek Pharmaceuticals, INC. | $16.57 | 2025 | Nuzyra, Xhance |
| Organon LLC | $16.18 | 2025 | Vtama |
| X4 Pharmaceuticals, INC. | $16.18 | 2024 | Xolremdi |
| Horizon Therapeutics Plc | $15.30 | 2020 | |
| Hikma Pharmaceuticals USA | $14.48 | 2023 | Ryaltris |
| Mallinckrodt Hospital Products INC. | $14.13 | 2022 | |
| Octapharma USA, INC. | $13.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Ricketti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.